2 results
Approved WMOCompleted
Primary Objective: To determine whether topical application of Calcitriol (Silkis) 3 µg/g, Diclofenac 10% or a combination of both can lead to a 40% histological reduction (*)/increase (*) of expression of the following antibodies: Ki67 (*), BCL2…
Approved WMORecruiting
The purpose of the study is to provide ongoing post-market demonstration of the safety and performance of the FARAPULSEPulsed Field Ablation System in the treatment of patients with paroxysmal atrial fibrillation (PAF).